Elia De Maria

Dr. Elia De Maria

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 December 2014 in Current Cardiology Reviews
Verified
Journal Article
Open access
EMElia De Maria
Elia De Maria
AOAlina Olaru
Alina Olaru
SCStefano Cappelli
Stefano Cappelli

1 January 2017 in World Journal of Cardiology
Verified
Journal Article
Open access
EMElia De Maria
Elia De Maria
DGDaniele Giacopelli
Daniele Giacopelli
ABAmbra Borghi
Ambra Borghi
LMLetizia Modonesi
Letizia Modonesi
SCStefano Cappelli
Stefano Cappelli
Implantable cardioverter defibrillator (ICD) programming involves several parameters. In recent years antitachycardia pacing (ATP) has gained an increasing importance in the treatment of ventricular arrhythmias, whether slow or fast. It reduces the number of unnecessary and inappropriate shocks and improves both patient’s quality of life and device longevity. There is no clear indication regarding the type of ATP to be used, except for the treatment of fast ventricular tachycardias (188 bpm-250 bpm) where it has been shown a greater efficacy and safety of burst compared to ramp; 8 impulses in each sequence of ATP appears to be the best programming option in this setting. Beyond ATP use, excellent clinical results were obtained with programming standardization following these principles: extended detection time in ventricular fibrillation (VF) zone; supraventricular discrimination criteria up to 200 bpm; first shock in VF zone at the maximum energy in order to reduce the risk of multiple shocks. The MADIT-RIT trial and some observational registries have also recently demonstrated that programming with a widespread use of ATP, higher cut-off rates or delayed intervention reduces the number of inappropriate and unnecessary therapies and improves the survival of patients during mid-term follow-up.

16 June 2017 in European Journal of Preventive Cardiology
Verified
Journal Article
Open access
MLMaddalena Lettino
Maddalena Lettino
SLSergio Leonardi
Sergio Leonardi
EMElia De Maria
Elia De Maria
SHSigrun Halvorsen
Sigrun Halvorsen
Platelets play a key role in the pathogenesis of acute coronary syndromes and this is why antiplatelet drugs are essential, both in the acute phase and in the long-term follow-up in preventing recurrent myocardial infarction, stroke and cardiovascular death. Aspirin is the most used agent and still remains the first choice drug for lifelong administration in secondary prevention after myocardial infarction. Dual antiplatelet therapy, targeting more than one pathway of platelet activation, has significantly improved the outcome of patients with acute coronary syndromes despite an increased risk of bleeding complications. The aim of this article is to provide an overview of the evidence from randomized clinical trials with a focus on the best association between aspirin and a P2Y12 inhibitor such as clopidogrel, prasugrel or ticagrelor, on the selection of the appropriate agent based on the revascularization strategy and on the optimal duration of such an intensive treatment. We will also provide the latest evidence regarding new antithrombotic agents, such as vorapaxar or low dose rivaroxaban, that could be associated with dual antiplatelet therapy in high risk patients with the aim of further reducing the rate of major ischaemic complications. Finally we will address the issue of patients presenting with atrial fibrillation and a concomitant acute coronary syndrome who frequently need a percutaneous coronary intervention, with a specific focus on the combination therapy of antiplatelet and anticoagulant agents and on the current recommendations of the guidelines.

1 January 2017 in World Journal of Clinical Cases
Verified
Journal Article
Open access
EMElia De Maria
Elia De Maria
ABAmbra Borghi
Ambra Borghi
LMLetizia Modonesi
Letizia Modonesi
SCStefano Cappelli
Stefano Cappelli
Ticagrelor is a potent, direct P2Y12 antagonist with rapid onset of action and intense platelet inhibition, indicated in patients with acute coronary syndromes (ACS). This drug is usually well tolerated, but some patients experience serious adverse effects: Major bleeding; gastrointestinal disturbances; dyspnoea; ventricular pauses > 3 s. Given the unexpected high incidence of bradyarrhythmias, a PLATO substudy monitored this side effect, showing that ticagrelor was associated with an increase in the rate of sinus bradycardia and sinus arrest compared to clopidogrel. This side effect was usually transient, asymptomatic and not associated with higher incidence of severe atrioventricular (AV) block or pacemaker needs. A panel of experts from Food and Drug Administration did not consider bradyarrhythmias a serious problem in clinical practice and, accordingly, current labeling of the drug does not give any precaution or contraindication regarding this issue. However, recently some articles have described ACS patients with high-degree, life-threatening, AV block requiring drug discontinuation and, in some cases, pacemaker implantation. In this paper, we describe and discuss five published case reports of severe AV block following ticagrelor therapy and two other cases managed in our Hospital. The analysis of literature suggests that, although rarely, ticagrelor can be associated with life-threatening AV block. Caution and careful monitoring are required especially in patients with already compromised conduction system and/or treated with AV blocking agents. Future studies, with long-term rhythm monitoring, would help to define the outcome of patients at higher risk of developing this complication.

13 October 2011 in Journal of Interventional Cardiac Electrophysiology
Verified
Journal Article
Closed access
EMElia De Maria
Elia De Maria
LBLorenzo Bonetti
Lorenzo Bonetti
GPGiampiero Patrizi
Giampiero Patrizi
JSJohn Scrivener
John Scrivener
AAAlberto Andraghetti
Alberto Andraghetti
SCStefano Cappelli
Stefano Cappelli

1 December 2013 in Heart Rhythm
Verified
Journal Article
Closed access
EMElia De Maria
Elia De Maria
SCStefano Cappelli
Stefano Cappelli
RCRiccardo Cappato
Riccardo Cappato